Kura Oncology(KURA) - 2023 Q4 - Earnings Call Presentation

KOMET-001 Phase 1/2 Study of Ziftomenib in Relapsed/Refractory AML Ziftomenib Demonstrates Optimal Pharmaceutical Properties • No dose adjustment of ziftomenib needed when administered with a CYP3A4 inhibitor (e.g., azoles) 10 • Rates of DS in KMT2A-r monotherapy patients were 38.5% at 200 mg and 37.5% at 600 mg; potential to mitigate in combination Fathi et al. EHA 2023 #LB2713 (preliminary data as of April 12, 2023) 11 40% of NPM1 patients achieved a CR during course of study High activity, durable respon ...